Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 501–600 of 937
Yu, B. D., Becker-Hapak, M., Snyder, E. L., Vooijs, M., Denicourt, C., & Dowdy, S. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2431391100 · Cited by 42
Lung, J. C., Chu, J., Yu, J., Yue, C., Lo, Y., Shen, C., & Wu, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10072 · Cited by 46
“Interestingly, a recent finding that cyclin D1-deficient mice are resistant to breast cancer confirms an initiating role of this gene during breast tumorigenesis (Yu et al., 2001), is consistent with our suggestion that cyclin D1 overexpression occurs early during breast cancer progression, and serves as an important…”
BackgroundGallagher, R., Hay, T., Méniel, V. S., Naughton, C., Anderson, T. J., Shibata, H., Ito, M., Clevers, H. C., Noda, T., Sansom, O. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205892 · Cited by 41
“Cyclin D1 has recently been shown to be central to ras and neu mediated mammary oncogenesis, although this despondency apparently does not extend to pathways driven by c-myc or Wnt1 (Yu et al., 2001).”
BackgroundInfluentialWang, Y., Thakur, A. B., Sun, Y., Wu, J., Biliran, H., Bollig-Fischer, A. B., & Liao, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4000 · Cited by 45
“Unlike mammary carcinogenesis induced by neu and H-ras , mammary carcinogenesis induced by MMTV-c-myc or Wnt does not require cyclin D1 because tumors can develop in cyclin D1 knockout mice (4).”
BackgroundETS‐targeted therapy: can it substitute for MEK inhibitors?
Tetsu, O., & McCormick, F. P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0147-4 · Cited by 45
“The critical role of cyclin D1 for MAPK-mediated oncogenesis was established first in the murine model for skin cancer [45] and later for breast cancer [46].”
BackgroundEryngium Billardieri Induces Apoptosis via Bax Gene Expression in Pancreatic Cancer Cells
Roshanravan, N., Asgharian, P., Dariushnejad, H., Alamdari, N. M., Mansoori, B., Mohammadi, A., Alipour, S., Barati, M., Ghavami, A., Ghorbanzadeh, V., et al. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.075 · Cited by 40
“A correlation has previously been pointed out between increased cyclin D1 and cancer formation.(30,31) Based on the results of this study,”
ResultGrizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
Cho, E. Y., Han, J. J., Choi, Y., Kim, K., & Oh, Y. L. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.6.1053 · Cited by 44
Animal Transgenesis and Cloning
Houdebine, L. (2003) · Wiley eBooks · doi:10.1002/0470867280 · Cited by 49
Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx
Rydzanicz, M., Golusiński, P., Mielcarek-Kuchta, D., Golusiński, W., & Szyfter, K. (2005) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-005-0957-7 · Cited by 39
“In animal models, deregulated cyclin D1 expression has been associated with increased genetic instability, cell proliferation and promotion of tumorigenesis [28, 31, 40]; mice deficient in cyclin D1 are resistant to cancer development [38].”
BackgroundSpofford, L. S., Abel, E. V., Boisvert-Adamo, K., & Aplin, A. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600197200 · Cited by 42
Yin, Y., Katz, V., Salah, Z., Maoz, M., Cohen, I., Uziely, B., Turm, H., Grisaru‐Granovsky, S., Suzuki, H., & Bar‐Shavit, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4234 · Cited by 41
Hulit, J., Lee, R. J., Li, Z., Wang, C., Katiyar, S., Yang, J., Quong, A. A., Wu, K., Albanese, C., Russell, R. G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0149 · Cited by 41
Yang, C., Chen, L., Li, C., Lynch, M. C., Brisken, C., & Schmidt, E. V. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01398-09 · Cited by 44
“This model implies an additional potential explanation for the decreased tumor formation seen in erbB2 and ras transgenic mice when they are cyclin D1 null (50), since the decreased tumorigenesis could result from loss of PR function and/or loss of cell cycle control.”
Backgroundβ-Ionone arrests cell cycle of gastric carcinoma cancer cells by a MAPK pathway
Dong, H., Zhang, S., Sun, W., Liu, Q., Ibla, J. C., Soriano, S. G., Han, X., Liu, L., Li, M., & Liu, J. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1041-5 · Cited by 42
Kouvaraki, M. A., Gorgoulis, V. G., Rassidakis, G. Z., Liodis, P., Markopoulos, C. J., Gogas, J. G., & Kittas, C. N. (2002) · Cancer · doi:10.1002/cncr.10505 · Cited by 39
“Moreover, it has been shown recently that cyclin D1 may be the target of c-erb-B2– and Ras-mediated oncogenic pathways.(53) Of note, recent molecular studies suggest that p27 and other CDK inhibitors of Cip/Kip family, in contrast with their inhibitory function for cyclin E– and cyclin A– dependent CDKs, also may act…”
BackgroundGene regulation by SMAR1: Role in cellular homeostasis and cancer
Malonia, S. K., Sinha, S., Lakshminarasimhan, P., Singh, K., Jalota‐Badhwar, A., Rampalli, S., Kaul-Ghanekar, R., & Chattopadhyay, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.08.003 · Cited by 39
Telomerase activates transcription of cyclin D1 gene through an interaction with NOL1
Hong, J., Lee, J. H., & Chung, I. K. (2016) · Journal of Cell Science · doi:10.1242/jcs.181040 · Cited by 41
Roy, A., Ansari, S. A., Das, K., Prasad, R., Bhattacharya, A., Mallik, S., Mukherjee, A. K., & Sen, P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.764670 · Cited by 41
Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis
Gan, L., Liu, P., Lu, H., Chen, S., Yang, J., McCarthy, J. B., Knudsen, K. E., & Huang, H. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.86 · Cited by 44
LRH1 as a driving factor in pancreatic cancer growth
Lin, Q., Aihara, A., Chung, W., Li, Y., Huang, Z., Chen, X., Weng, S., Carlson, R. I., Wands, J. R., & Dong, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.014 · Cited by 38
“The cell cycle regulators cyclin D1/E1 are frequently overexpressed in gastrointestinal tumors [11] and contribute to oncogenesis in animal models [16].”
Role of I?B kinase in tumorigenesis
Hu, M. C. ‐., & Hung, M. (2005) · Future Oncology · doi:10.1517/14796694.1.1.67 · Cited by 39
“In addition, cyclin D1 has been suggested to be an essential NF-κB target genes in normal mammary gland development and breast tumorigenesis [29,30].”
BackgroundMohammadinejad, S., Akbarzadeh, A., Rahmati‐Yamchi, M., Hatam, S., Kachalaki, S., Sanaat, Z., & Zarghami, N. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3753 · Cited by 38
“Overexpression of cyclin D1 has been reported to be directly associated with tumorigenicity, poor prognosis and resistance to therapy in several cancer cell lines including breast cancer (Hosokawa and Arnold, 1998; Yu et al., 2001; Fu et al., 2004).”
BackgroundWilding, J., Straub, J., Bee, J., Churchman, M., Bodmer, W. F., Dickson, C., Tomlinson, I. P. M., & Ilyas, M. (2002) · PubMed · Cited by 45
Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer
Menezes, M. E., Das, S. K., Emdad, L., Windle, J. J., Wang, X., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00008-1 · Cited by 42
The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2
Watanabe, M., Iizumi, Y., Sukeno, M., Iizuka-Ohashi, M., Sowa, Y., & Sakai, T. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.10 · Cited by 38
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
TAN, A., & Swain, S. M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70130-9 · Cited by 41
Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.
Wang, X., Yu, B., Wu, Y., Lee, R. J., & Lee, L. J. (2011) · PubMed · Cited by 41
Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome
Wang, G., Gormley, M., Qiao, J., Zhao, Q., Wang, M., Sante, G. D., Deng, S., Lin, D., Pestell, T. G., Ju, X., et al. (2018) · Theranostics · doi:10.7150/thno.23877 · Cited by 37
“Cyclin D1 is required for the growth of cultured breast cancer cells and is necessary for the growth of oncogene-induced breast tumors in mice [2, 3].”
BackgroundLaphanuwat, P., Likasitwatanakul, P., Sittithumcharee, G., Thaphaengphan, A., Chomanee, N., Suppramote, O., Ketaroonrut, N., Charngkaew, K., Lam, E. W. ‐., Okada, S., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.214726 · Cited by 43
“Activation of the Kras or HER2 pathways targeted in mouse breast tissue resulted in breast cancer, but failed to induce any tumors in breasts of cyclin D1-deficient mice (Yu et al., 2001).”
BackgroundDall’Acqua, A., Bartoletti, M., Masoudi-Khoram, N., Sorio, R., Puglisi, F., Belletti, B., & Baldassarre, G. (2021) · Cancers · doi:10.3390/cancers13123035 · Cited by 41
“This hypothesis has been experimentally validated in mice, demonstrating, for instance, that mice lacking cyclin D1, or Cdk4, or mice expressing kinase-deficient cyclin D1-Cdk complexes were resistant to HER2- or Ras-driven mammary tumorigenesis, but not to the one sustained by c-Myc overexpression [11,12].”
BackgroundViganò, L., Locatelli, A., Ulisse, A., Galbardi, B., Dugo, M., Tosi, D., Tacchetti, C., Daniele, T., Győrffy, B., Sica, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3185 · Cited by 45
Abramson, V. G., Troxel, A. B., Feldman, M. D., Mies, C., Wang, Y., Sherman, L. S., McNally, S., Diehl, J. A., & DeMichele, A. M. (2010) · PubMed · Cited by 39
Hunk is required for HER2/neu-induced mammary tumorigenesis
Yeh, E. S., Yang, T. W., Jung, J. J., Gardner, H. P., Cardiff, R. D., & Chodosh, L. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42928 · Cited by 38
Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53
Padmakumar, V. C., Aleem, E. A., Berthet, C., Hilton, M. B., & Kaldis, P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00952-08 · Cited by 41
“While it has been shown that cancer cells can still proliferate in the absence of Cdk2, Cdk4 activity was reported to be essential for ErbB-2-driven mammary carcinogenesis (46, 47).”
BackgroundReed, W., Sandstad, B., Holm, R., & Nesland, J. M. (2003) · International Journal of Surgical Pathology · doi:10.1177/106689690301100201 · Cited by 36
“Possibly, amplification of c-erbB-2 does not necessarily result in a high expression of cyclin DI, as c-erbB-2 gene seems to regulate the promoter region of the cyclin DI gene, a region that does not encode the protein product, but is needed to control gene expression [56].”
BackgroundCyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
Li, Z., Chen, K., Jiao, X., Wang, C., Willmarth, N. E., Casimiro, M. C., Li, W., Ju, X., Kim, S. H., Lisanti, M. P., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3137 · Cited by 43
D’Amico, M., Wu, K., Fu, M., Rao, M., Albanese, C., Russell, R. G., Lian, H., Bregman, D. B., White, M. A., & Pestell, R. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2519 · Cited by 45
“or 600 ng of expression vector as indicated in the figure legend (3,4,6,8) and”
Huth, H. W., Albarnaz, J. D., Torres, A. A., Bonjardim, C. A., & Ropert, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.05.009 · Cited by 37
Chen, H., Xu, X., Wang, G., Zhang, B., Wang, G., Xin, G., Liu, J., Jiang, Q., Zhang, H., & Zhang, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.773226 · Cited by 39
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Cancers · doi:10.3390/cancers12020308 · Cited by 37
“Cyclin D1 deficiency has been shown to impair mammary epithelial proliferation [99] while cyclin D1 and CDK4 are necessary for breast cancer development in mice [100] and cyclin D1 is overexpressed in the majority of human breast cancers [101].”
BackgroundInhibition of TFII-I-Dependent Cell Cycle Regulation by p53
Desgranges, Z. P., Ahn, J., Lazebnik, M. B., Ashworth, T. D., Lee, C., Pestell, R. G., Rosenberg, N. E., Prives, C. L., & Roy, A. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10940-10952.2005 · Cited by 35
“It has been shown recently that cyclin D1 upregulation leads to chromosomal abnormalities (45), while reduced levels of cyclin D1 is protective from tumorgenesis (15, 29, 65).”
BackgroundZhang, Q., Sakamoto, K., Liu, C., Triplett, A. A., Lin, W.-C., Rui, H., & Wagner, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1783 · Cited by 37
“Downregulation of Cyclin D1 has no effect on the growth of ErbB2-induced mammary cancer cells Although it was reported that Cyclin D1-deficient mice are resistant to ErbB2-induced mammary carcinogenesis (10, 11), it has never been examined whether the ablation of this cellcycle regulator has an impact on the growth of…”
InfluentialAcute and chronic cadmium exposure promotes E‐cadherin degradation in MCF7 breast cancer cells
Ponce, E., Louie, M. C., & Sevigny, M. B. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22170 · Cited by 37
Wang, L., Zhang, R., You, X., Zhang, H., Wei, S., Cheng, T., Cao, Q., Wang, Z., & Chen, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx028 · Cited by 41
“In addition, CDK4 and cyclin D1 are required for breast cancer tumorigenesis (Yu et al., 2001, 2006; Reddy et al., 2010).”
BackgroundSynthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors
Cui, G., Jin, J., Chen, H., Cao, R., Chen, X., & Xu, B. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.024 · Cited by 36
Minami, Y., Kohsaka, S., Tsuda, M., Yachi, K., Hatori, N., Tanino, M. A., Kimura, T., Nishihara, H., Minami, A., Iwasaki, N., et al. (2014) · Cancer Science · doi:10.1111/cas.12479 · Cited by 34
Cooperation between Dmp1 Loss and Cyclin D1 Overexpression in Breast Cancer
Zhu, S., Mott, R. T., Fry, E. A., Taneja, P., Kulik, G., Sui, G., & Inoue, K. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.06.027 · Cited by 34
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
“Cyclin D1 is a direct transcriptional target of ER(8) and is essential for mammary tumorigenesis in mice.(9) Activation of the CDK4/CDK6/cyclin D complex also contributes to ET resistance in breast cancer FIGURE 1.”
BackgroundCheng, G., Zhang, L., Lv, W., Dong, C., Wang, Y., & Zhang, J. (2014) · Medical Oncology · doi:10.1007/s12032-014-0439-0 · Cited by 38
“Previous studies have suggested that cyclin D1 is highly expressed in cells derived from breast, gastric, esophageal and colon cancer, as well as glioblastomas [7, 9, 12, 13, 15], but it is still unclear whether and how this multifunctional protein contributes to tumorigenicity in meningioma.”
BackgroundErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo
Casimiro, M. C., Rodriguez, O. C., Pootrakul, L., Aventian, M., Lushina, N., Cromelin, C., Ferzli, G. M., Johnson, K., Fricke, S. T., Diba, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1898 · Cited by 34
Wu, F., Luo, L., Liu, Y., Zhan, Q.-X., Luo, C., Luo, J., Zhang, G., & Feng, Z. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.044 · Cited by 35
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 38
ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1
Hulit, J., Lee, R. J., Russell, R. G., & Pestell, R. G. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01145-0 · Cited by 38
Moustafa, A. A., Foulkes, W. D., Wong, A., Jallal, H., Batist, G., Yu, Q., Herlyn, M., Siciński, P., & Alaoui‐Jamali, M. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207679 · Cited by 38
“Furthermore, they demonstrated that the cyclin D1 gene is a target of cell transformation induced by Ras/Neu (rat ErbB-2) cooperation (Yu et al., 2001).”
BackgroundSelf-citationConvergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle
Agami, R., & Bernards, R. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00785-6 · Cited by 39
Kröger, A., Stirnweiß, A., Pulverer, J. E., Klages, K., Grashoff, M., Reimann, J., & Häuser, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3564 · Cited by 41
“to skin and mammary tumors induced by ras and ErbB-2 expression (26, 27).”
BackgroundSelective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis
Wu, L., de Bruin, A., Wang, H. E., Simmons, T., Cleghorn, W. M., Goldenberg, L. E., Sites, E. R., Sandy, A., Trimboli, A. J., Fernandez, S. A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.511 · Cited by 34
“E2F activators are up-regulated in ErbB2 -overexpressing human primary mammary carcinomas Considering that ErbB2-or Ras-mediated mammary tumorigenesis in mice is strictly dependent on Cyclin D1, 41 which has been shown to activate E2f activators through phosphorylation and inactivation of Rb , we decided to assess whe…”
InfluentialSpring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 36
Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?
Musgrove, E. A. (2003) · Breast Cancer Research · doi:10.1186/bcr737 · Cited by 33
“MMTV-Wnt-1 mice [30], and in HC11 cells expressing Wnt-1 (but not Wnt-5A) [3].”
BackgroundCyclin D1 expression in melanocytic lesions of the skin
Ramirez, J. A., Guitart, J., Rao, M. S., & Diaz, L. K. (2005) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2005.04.018 · Cited by 33
“In addition, cyclin D1 protein overexpression with or without gene amplification has been reported in a variety of malignant human tumors such as breast, colon, lung, head/neck, bladder, and mantle cell lymphomas [6-16].”
BackgroundPin1 contributes to cervical tumorigenesis by regulating cyclin D1 expression
Li, H., Wang, S., Zhu, T., Zhou, J., Xu, Q., Lu, Y., & Ma, D. (2006) · Oncology Reports · doi:10.3892/or.16.3.491 · Cited by 33
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice
Strumane, K., Rygiel, T. P., van der Valk, M., & Collard, J. G. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0437-8 · Cited by 34
“Moreover, both the Ras and Neu oncogenes are absolutely dependent on cyclin D1 expression for mammary tumor formation in MMTVras and MMTV-c-neu transgenic mice (Yu et al. 2001).”
Cyclin D1 down-regulation is essential for DBC2’s tumor suppressor function
Yoshihara, T., Collado, D., & Hamaguchi, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.037 · Cited by 33
“It was demonstrated that RAS and c-erb-B2 absolutely depend on CCND1 to trigger malignant transformations, but other genes do not [10].”
BackgroundFleming, I. N., Hogben, M., Frame, S., McClue, S. J., & Green, S. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4633 · Cited by 35
Sakamoto, K., Lin, W.-C., Triplett, A. A., & Wagner, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0746 · Cited by 35
“Therefore, this observation challenges the current view about the importance of cyclin D1 in the initiation of ErbB2-associated mammary cancer (11, 35, 36).”
BackgroundTranslational regulation of cyclin D1 by 15-deoxy-delta(12,14)-prostaglandin J(2).
Campo, P. A., Das, S., Hsiang, C., Bui, T., Samuel, C. E., & Straus, D. S. (2002) · PubMed · Cited by 33
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects
Barton, B. E., & Barton, B. E. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s32559 · Cited by 37
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells
Sarkar, S., Mazumdar, A., Dash, R., Sarkar, D., Fisher, P. B., & Mandal, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22343 · Cited by 32
“The alteration of both cyclin D1 and cyclin E was associated with breast cancer progression, early relapse, poor prognosis, and chemoresistance to various cytotoxic agents (Bortner and Rosenberg, 1997; Yu et al., 2001; Sgambato et al., 2003).”
BackgroundSante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 34
“In subsequent cyclin D1 gene knockout mouse experiments, cyclin D1 was shown to have a pivotal role in the induction of breast tumors by Ras or ErbB2 [96].”
InfluentialHarrison, M. K., Adon, A. M., & Saavedra, H. I. (2011) · Cell Division · doi:10.1186/1747-1028-6-2 · Cited by 37
“Along the same line, cyclin D and Cdk4 are required for neu and ras induced mammary tumorigenesis [139,140], demonstrating that the cyclin D1/Cdk4 complex is needed for mammary transformation.”
BackgroundCDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
“At the preclinical level, CCND1 was found to be essential for HER2-driven mammary tumorigenesis, but not for the formation of tumor driven by other oncogenic signaling pathways [61].”
BackgroundFrequent amplification and overexpression of CCND1 in male breast cancer
Barlund, M. T., Kuukasjärvi, T., Syrjäkoski, K., Auvinen, A. P., & Kallioniemi, A. H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20307 · Cited by 32
Nahta, R., Trent, S., Yang, C., & Schmidt, E. V. (2003) · PubMed · Cited by 32
Bártek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35082655 · Cited by 40
Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis
Dong, Y., Tine, B. A. V., Oyama, T., Wang, P. I., Cheng, E. H. Y., & Hsieh, J. J.-D. (2014) · Cell Research · doi:10.1038/cr.2014.129 · Cited by 32
Dynamic expression of a LEF‐EGFP Wnt reporter in mouse development and cancer
Currier, N. V., Chea, K., Hlavacova, M., Sussman, D. J., Seldin, D. C., & Dominguez, I. M. (2010) · genesis · doi:10.1002/dvg.20604 · Cited by 35
“However, studies in mice suggest that cyclin D1 may not be required for breast tumor formation induced by Wnt signaling (Yu et al., 2001).”
BackgroundTasseff, R. A., Nayak, S., Salim, S., Kaushik, P., Rizvi, N. F., & Varner, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008864 · Cited by 41
“Many studies have identified a direct correlation between cyclin D regulation and prostate cancer, as well as breast and non-small cell lung cancer [71–73].”
Backgroundda Rocha, K. M., Forti, F. L., Lepique, A. P., & Armelin, H. A. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10336 · Cited by 31
“In addition, cyclin D1 is amplified and overexpressed in a large proportion of human mammary carcinomas and also may have a causative role in breast cancer formation in transgenic mice, but cyclin D1 pathways display exquisite cell type specificity (Yu et al., 2001).”
BackgroundUtikal, J. S., Udart, M., Leiter, U., Peter, R. U., & Krähn, G. M. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.3.597 · Cited by 31
Cell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
Chin, Y. M., Shibayama, T., Chan, T., Otaki, M., Hara, F., Kobayashi, T., Kobayashi, K., Hosonaga, M., Fukada, I., Inagaki, L., et al. (2022) · Cancer Science · doi:10.1111/cas.15304 · Cited by 36
Nuclear factor-κB as a predictor of treatment response in breast cancer
Garg, A. K., Hortobágyi, G. N., Aggarwal, B. B., Şahin, A. A., & Buchholz, T. A. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00001 · Cited by 30
Rodriguez‐Viciana, P., & McCormick, F. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.012 · Cited by 30
v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1
Ju, X., Jiao, X., Ertel, A., Casimiro, M. C., Sante, G. D., Deng, S., Li, Z., Rocco, A. D., Zhan, T., Hawkins, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3327 · Cited by 31
“The abundance of cyclin D1 is rate limiting in growth of a variety of tumors in vivo, including ErbB2-induced breast cancer (3, 4) and a 50% reduction in cyclin D1 abundance in cyclin D1 heterozygote mice is sufficient to reduce the onset and progression of gastrointestinal tumorigenesis induced by the Apc/Min mutatio…”
BackgroundTherapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer
Seo, J.-H., Jeong, E.-S., & Choi, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-175 · Cited by 29
“Accordingly, inhibition of cyclin D1 may be an innovative strategy for cancer treatment [4,5].”
BackgroundCartilage polysaccharide induces apoptosis in human leukemia K562 cells
Liu, A., Song, W., Yang, N., LIU, Y.-J., & Zhang, G. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-007-9008-z · Cited by 30
“Overexpression of cyclin D1 has been implicated in the transformation and development of many types of cancer (Sherr 1996; Rosenwald et al. 1999; Yu et al. 1999).”
BackgroundGustafson, T. L., Wellberg, E. A., Laffin, B., Schilling, L., Metz, R. P., Zahnow, C. A., & Porter, W. W. (2009) · Oncogene · doi:10.1038/onc.2008.497 · Cited by 29
“Harvey-Ras (Ha-Ras)-induced tumors are characterized by activation of mitogen-activated protein kinase signaling and are cyclin D1 dependent (Yu et al., 2001; Dunn et al., 2005).”
BackgroundTransgenic mouse models for the prevention of breast cancer
Shen, Q., & Brown, P. H. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.10.013 · Cited by 32
Genes related to estrogen action in reproduction and breast cancer
Aninda, B. (2005) · Frontiers in bioscience · doi:10.2741/1703 · Cited by 31
“Cyclin D1-/- mouse studies suggested an important role for cyclin D1 in erbB2-induced mammary tumorigenesis (107,108).”
BackgroundPirkmaier, A., Dow, R., Ganiatsas, S., Waring, P., Warren, K., Thompson, A., Hendley, J., & Germain, D. (2003) · Oncogene · doi:10.1038/sj.onc.1206488 · Cited by 29
“Further, cyclin D1 knockout mice show a defect in mammary gland proliferation during pregnancy (Sicinski and Weinberg, 1997; Fantl et al., 1999) and cyclin D1 was shown recently to be essential for tumor formation in MMTVras and MMTV-erbB-2 transgenic models (Yu et al., 2001).”
BackgroundCyclin D1 promotes secretion of pro-oncogenic immuno-miRNAs and piRNAs
Lü, J., Zhao, Q., Ding, X., Guo, Y., Li, Y., Xu, Z., Li, S., Wang, Z., Shen, L., Chen, H.-W., et al. (2020) · Clinical Science · doi:10.1042/cs20191318 · Cited by 29
Jirawatnotai, S., Sharma, S., Michowski, W., Suktitipat, B., Geng, Y., Quackenbush, J. F., Elias, J. E., Gygi, S. P., Wang, Y. E., & Siciński, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946850 · Cited by 30
“Mouse 3T3 cells were generated as described.(46) All cell lines were maintained in high glucose DMEM with 10% fetal bovine serum (FBS) plus penicillin/streptomycin, except Z138 and U2OS cells that were grown in RPMI1640 and McCoy’s medium, respectively, with 10% FBS plus and penicillin/streptomycin, Tandemly tagged CD…”
MethodSelf-citationMacias, E., Kim, Y., de Marval, P. L. M., Klein–Szanto, A. J., & Rodríguez‐Puebla, M. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2119 · Cited by 30
“For instance, cyclin D1-deficient mice are resistant to breast cancers induced by ras, but remains fully sensitive to other oncogenic pathways such as those driven by myc or Wnt-1 (50).”
BackgroundMusgrove, E. A., Davison, E. A., & Ormandy, C. J. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023588.55733.84 · Cited by 35
“This conclusion is supported by the observation that when mice with mammary-directed wild-type or activated Neu are crossed onto a cyclin D1-null background, tumor formation is substantially impaired (54,55).”
Competition on Nitrocellulose-immobilized Antibody Arrays
Yeretssian, G., Lecocq, M., Lebon, G., Hurst, H. C., & Sakanyan, V. A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400181-mcp200 · Cited by 28
“In breast epithelial cells, ErbB2 lies upstream of Ras in the mitogenic signaling pathway (39), which leads to transcriptional induction of cyclin D1 (40, 41).”
BackgroundInfluentialCyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility
Fernández-Hernández, R., Ruiz-Miró, M., Dolcet, X., Aldea, M., & Garí, E. (2011) · Oncogene · doi:10.1038/onc.2010.577 · Cited by 34
“In accordance with the importance of CycD1 in cellular transformation, CycD1-deficient mice are resistant to the development of apc-induced gastrointestinal tumors and ras-induced mammary tumors (Yu et al., 2001; Hulit et al., 2004).”
BackgroundSynthesis and cytotoxicity of 2-phenylquinazolin-4(3H)-one derivatives
Rhee, H., Yoo, J. H., Lee, E., Kwon, Y., Seo, H. R., Lee, Y., & Choo, H. P. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.061 · Cited by 27
Cyclin‐dependent kinases as therapeutic targets in melanoma
Miller, D. M., & Flaherty, K. T. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12211 · Cited by 32
“Primary keratinocytes (Robles et al., 1998) and mammary gland cells (Yu et al., 2001) from Ccnd1null mice are protected against HRAS-mediated transformation.”
BackgroundJiang, N., Lin, J., Wang, J., Zhang, B., Li, A., Chen, Z., Guo, S., Li, B., Duan, Y., Yan, R., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6459 · Cited by 67
“It has been proven that CCND1 and CDK4 played a vital role in BC (77,78).”
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.